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Abstract
Background: Oral bisphosphonates (BPs) are the primary agents for the treatment of osteoporosis. Although BPs are
generally well tolerated, serious gastrointestinal adverse events have been observed.
Aim: To assess the risk of severe upper gastrointestinal complications (UGIC) among BP users by means of a large study
based on a network of Italian healthcare utilization databases.
Methods: A nested case-control study was carried out by including 110,220 patients aged 45 years or older who, from 2003
until 2005, were treated with oral BPs. Cases were the 862 patients who experienced the outcome (hospitalization for UGIC)
until 2007. Up to 20 controls were randomly selected for each case. Conditional logistic regression model was used to
estimate odds ratio (OR) associated with current use of BPs after adjusting for several covariates. A set of sensitivity analyses
was performed in order to account for sources of systematic uncertainty.
Results: The adjusted OR for current use of BPs with respect to past use was 0.94 (95% CI 0.81 to 1.08). There was no
evidence that this risk changed either with BP type and regimen, or concurrent use of other drugs or previous
hospitalizations.
Conclusions: No evidence was found that current use of BPs increases the risk of severe upper gastrointestinal
complications compared to past use.
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Introduction
Osteoporosis is a condition characterized by low bone mineral
density and alterations of the microarchitecture of the skeleton that
determines fragility of the bone and subsequent increased risk of
fracture, even in case of mild traumas [1]. Approximately 75
million subjects in Europe, Japan and USA are affected by
osteoporosis [2].
Bisphosphonates (BPs), such as alendronate and risedronate, are
considered mainstay therapy for the treatment of osteoporosis.
Randomised clinical trials (RCTs) have consistently shown that
treatment with these agents improves bone mineral density (BMD)
and reduces bone fracture risk [3–9]. However, long-term therapy
is necessary to increase and maintain BMD and to maintain
normal levels of bone resorption [10]. Therefore, therapy must be
generally safe, besides being effective, in a long-term fashion. Data
from the pivotal RCTs of both alendronate [3–5] and risedronate
[7–9,11,12] did not find clinical evidence of adverse effects greater
than placebo. However, soon after alendronate release, many
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cases of oesophageal ulcerations were encountered, so resulting in
changes to the alendronate label [13,14]. From then on nowadays,
inconsistent findings on gastrointestinal (GI) safety of BPs have
been reported [15–20]. Two meta-analyses on this topic came to
conflicting conclusions [21,22], suggesting that evidence are still
insufficient to assess the gastrointestinal safety of these agents.
The aim of this nested case-control study was to assess the
relationship between current use of BPs and the risk of
hospitalization for severe UGIC. Controlling for sources of
systematic uncertainty was of particular concern in this study.
Methods
Data source
Italian population is covered by the National Health Service
(NHS). The healthcare service delivered by NHS to its beneficia-
ries is associated with an automated system of databases including:
(i) an archive of residents who receive NHS assistance (i.e. the
whole resident population), reporting demographic and adminis-
trative data, as well the dates of starting and stopping to benefit
from NHS assistance; (ii) a public and private hospital discharge
database; and (iii) a database on outpatient drug prescriptions
reimbursable by the NHS.
The primary sources of data were the databases of the 13 Italian
territorial units participating at the AIFA-BEST project. This last
is a National collaborative study funded by the Italian Agency of
Drug (AIFA) which was aimed of assessing BPs safety profile in the
Italian clinical practice. Territorial units were four Regions
(Abruzzo, Emilia-Romagna, Marche and Toscana) and nine
Local Health Authorities (Caserta, Como, Gorizia, Latina, Lodi,
Milano, Monza, Sondrio and Varese). A population of about 17
million of beneficiaries of NHS residents in these territorial units
was covered by the corresponding databases, accounting for nearly
30% of the whole Italian population.
Hospital discharge diagnoses and drug prescriptions of each
patient were assessed through a record linkage procedure based on
the unique individual identification code (Regional Health Code)
consistently reported in all databases. In order to preserve privacy,
we replaced the original identification code with its digest that is
the image of the code through a cryptographic hash function – the
Secure Hash Algorithm (SHA-256). Such hash function makes
infeasible to obtain the original code from the digest, is
deterministic (i.e. the same digest is always associated to any
given individual) and collision-resistant (the probability that two
individuals are associated to the same code is insignificant). The
specific hash function used (SHA-256) is the industry standard [23]
and has been incorporated into the data extraction-transforma-
tion-load software produced by the University of Milano-Bicocca.
All data were drawn out by means of standardized queries
which were discussed and agreed upon in conference together with
the study protocol. Appendix S1 provides specific diagnostic
therapeutic codes used in our study.
Study cohort
The target population included all beneficiaries of NHS
residents in the above mentioned territorial units aged 45 years
or older. According to the 2001 Italian Census, this population
comprised 6,135,458 individuals. Of these, those who received at
least one dispensation of BP reimbursable by the NHS
(alendronate and risedronate) from July 1, 2003 until December
31, 2005 were identified, and the date of first dispensation was
designed as initial prescription.
Exclusion criteria regarded patients who, within six months
before the initial prescription, (i) BPs were already been dispensed
(in order of favouring the inclusion of newly treated individuals),
(ii) were hospitalized for osteoporotic fractures (in order to focus on
primary prevention of osteoporotic fractures), (iii) were hospital-
ized for gastrointestinal adverse events (in order to focus on
incident cases of UGIC during follow-up) or with diagnosis of
coagulation disorders, alcohol abuse, chronic liver disease, or
cancer (in order to exclude higher-risk patients). In addition,
patients who were registered as NHS beneficiaries from less than
six months prior the initial prescription, and those who did not
reach at least two months of follow-up, were also excluded to
ensure a sufficient time-window of wash out and of exposure to the
drugs of interest, respectively. The remaining patients constituted
the study base population.
Each member of the cohort accumulated person-years of follow-
up from the date of study entry until the earliest date among those
of outcome onset (hospital admission for UGIC) or censoring
(death, emigration or December 31, 2007).
Selection of cases and controls
A case-control study was nested into the cohort of BPs users.
Cases were the cohort members who during follow-up experienced
at least a hospitalization with primary or secondary diagnosis of
UGIC including: oesophageal/gastrointestinal ulcer, perforation
of oesophagus, oesophageal/gastrointestinal haemorrhage (see
Appendix S1). The earliest date of hospital admission recording
one of these events was considered as the index date.
Up to twenty controls for each case were randomly selected
from the cohort members to be matched for territorial unit of
recruitment, gender, age at study entry, date of initial prescription
and who survived at least as long as the index case. The index date
of each matched control was fixed as the same as the index date of
his case patient.
Exposure assessment
During the study period two drug types (alendronate and
risedronate) either on once-daily (10 mg/day and 5 mg/day,
respectively) or once-weekly (70 mg/week and 35 mg/week,
respectively) regimens were available for free reimbursement by
Italian NHS.
The length time with drug available for each refilled canister
was calculated assuming the standard frequency of intake and the
prescribed dosing regimen (i.e. two or four weeks). The date of
exposure stopping of each dispensation was accordingly estab-
lished. For overlapping prescriptions, individuals were assumed to
have refilled early and completed the first prescription before
starting the second. Exposure to BPs was categorized as ‘‘current,’’
when the supply of the most recent prescription lasted until the
index date or ended in the 30-day period prior the index date or
‘‘past’’, when the latest use was in the 31 days or more prior the
index date. Current users were further classified according to type
and regimen of the latest dispensed BP.
Because we had no information about drug prescriptions for
inpatients, with the aim of avoiding the so called immeasurable
time bias, i.e. the differential misclassification due to unmeasured
drug exposure during hospitalizations [24], the observation period
was temporarily censored at the date of hospital admission for a
cause that differed from UGIC, and re-established 10 days after
hospital discharge.
Covariates
For each case and control the occurrence of hospitalizations (for
any diagnosis that differed from UGIC), as well as the use of other
drugs over the 60-day period prior the index date were
investigated. Other drugs included antidepressants, antithrombot-
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ic, gastroprotective agents, corticosteroids, statins, calcium channel
blockers, other antihypertensive agents and nonsteroidal antiin-
flammatory agents (NSAIDs) (see Appendix S1).
Conventional analyses
Chi-square, or its version for the trend, was used when
appropriate to test the differences between cases and controls. A
conditional logistic regression model was fitted to estimate the
odds ratio (OR), as well as its 95% confidence interval (CI), of
UGIC in relation to current use of BPs, with respect to past use.
Adjustments were made for the above reported covariates.
The combined effects of current BPs exposure together with use
of other drugs, occurrence of hospitalizations and type and
regimen of the dispensed BP, were estimated by including the
corresponding interaction terms in a conditional logistic model.
Sensitivity analyses
The following five sets of sensitivity analyses were performed.
First, we verified if our estimates were affected by the adopted
criteria for defining UGIC. Data were analysed according to
alternative diagnostic criteria, i.e. those recently proposed by
Cadarette & coll. while investigating oral BPs safety [20], as well as
those used by a collaborative project aimed to exploit European
healthcare databases for drug safety signal detection, the so called
EU-ADR project [25].
Second, we verified if our estimates were affected by the
adopted criteria for defining current exposure. Data were analyzed
according to time-window of 7, 15 or 45 days prior the index date
for defining current use, alternative to 30 days as in the main
analysis.
Third, we verified if our estimates were affected by protopathic
bias, i.e. if the use of BPs among cases could have been attenuated
in the current period owing to the onset of early symptoms of
UGIC [26]. To control for such a bias, lag-time of 7, 15, 30 or 45
days prior the index date were used before starting the backward
clock for measuring current exposure.
Fourth, the robustness of our findings regarding potential bias
introduced by the inclusion into the cohort of prevalent BP users
was investigated. Let the observed BPs – UGIC association be
expressed by the sum of the BPs – UGIC associations among
prevalent and incident users weighted by the corresponding
prevalence. Hence, if only incident users had been included, the
true BPs – UGIC association would be estimated from the
following two quantities: (i) the proportion of prevalent BP users
possibly included into the investigated cohort (p); (ii) the BPs –
UGIC association expected among prevalent users. The propor-
tion of cohort members who had at least one BP prescription
within four years before the initial prescription (rather than within
six months as in the main analysis) was used to estimate the first
quantity. These data were only available for a subcohort of
patients recruited by some Local Health Authorities (Como, Lodi,
Milano, Monza, Sondrio and Varese). We subsequently allowed
the possible values of the BPs – UGIC association among
prevalent users to vary from 0.2 to 1 (i.e. with respect to no BP
users in the current period, those who currently used BPs may
have experienced UGIC hospitalization up to 5-fold less).
Fifth, the robustness of our findings with regard to potential bias
introduced by unmeasured confounders was investigated by using
the rule-out approach described by Schneeweiss [27]. In applying
the rule-out method, we allowed the possible unmeasured
confounder (i) to be associated with the outcome with risk ratio
varying from 1 to 10 (i.e. the exposed patients to this factor may
have experienced hospitalization for UGIC up to 10-fold more, or
less, than unexposed), (ii) to be associated with the exposure of
interest with odds ratio varying from 1 to 10 (i.e. current users of
BPs may be exposed to this factor up to 10-fold more, or less, than
patients who currently do not use BPs), and (iii) to be present in the
study population with a prevalence 10%, 25% or 50%. In its
original formulation, rule-out approach aims to detect the
extension of confounding required to fully account for the
observed exposure-outcome association so moving the observed
point estimate to the null. In our application, we generalized the
use of the rule-out approach at the situations in which the
observed association did not reach statistical significance and the
interest was to detect the extension of confounding required to
make statistically significant the observed exposure-outcome
association. With this aim, we conducted the analysis for the
value of the observed lower 95% confidence limit to determine the
constellations in which the 95% confidence interval would not
cross the expected value under the null hypothesis.
The SAS statistical package was used for the analyses (SAS,
Version 9.1; SAS Institute, Cary, North Carolina, USA). For all
hypotheses tested two-tailed p-values less than 0.05 were
considered to be significant.
Ethical considerations
According to the rules from the Italian Medicines Agency
(available at: http://www.agenziafarmaco.gov.it/sites/default/
files/det_20marzo2008.pdf) retrospective studies without direct
contact with patients do not need a written consent to process
personal data when they are used for research aims. AIFA and the
Independent Ethics Committees (IEC) of all the territorial units
involved in the investigation (please, see Appendix S2 for the
complete IEC list) approved the study protocol.
Results
Sample selection
The distribution of the exclusion criteria is shown in Figure 1.
At entry, the 110,220 patients who were included into the study
had mean age of 70.9 years (SD 10.3) and 86.1% of them were
women. During follow-up these patients accumulated 335,845
person-years of observation and generated 862 hospital admissions
for UGIC, with an incidence rate of 26 cases per 10,000 person-
years. The 862 patients who experienced hospitalization for UGIC
(case patients) were matched to 15,505 controls.
Patients
At the date of the initial prescription, mean age of cases and
controls was almost 76.7 years (SD: 8.6), and nearly 81% of them
were women (matching variables). As shown in Table 1, current
use of BPs was more frequent among controls than cases.
Conversely, case patients used more frequently the other
considered drugs (with the exception of statins and calcium
channel blockers) and also experienced more hospitalizations than
controls.
Current use of bisphosphonates and the risk of upper
gastrointestinal complications
There was no evidence that current BP users had increased
UGIC risk with respect to past users either from unadjusted and
adjusted estimates (being the corresponding OR, and 95% CI,
respectively, 0.92, 0.80 to 1.06 and 0.94, 0.81 to 1.08, Figure 2).
Figure 2 also shows that there was no evidence that the ORs were
heterogeneous across patients stratified according with either types
or regimens of dispensed BPs, concurrent use of other drugs and
number of previous hospitalizations.
Bisphosphonates and Gastrointestinal Complications
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Sensitivity analyses
Figure 3 shows that OR substantially did not change by varying
criteria for diagnosis of UGIC (box A) and the length of the time-
window defining current BPs use (box B), neither by introducing
lag-time periods to take into account possible protopathic bias
(box C).
Figure 4 shows the robustness of our findings with regard to
potential bias by prevalent users. Let us assume a 12.8%
proportion of prevalent BPs users, i.e. the prevalence estimated
from the subcohort for which these data were available.
Furthermore, let us suppose that prevalent users currently exposed
to BPs have a two-fold decreased UGIC risk than those
unexposed. Then, the true BPs – UGIC association was about
1.0, i.e. the expected value under the null. However, even
supposing a much higher apparent (biased) protective BPs effect
among prevalent users (e.g. a five-fold reduced risk) a 5%
increased risk associated with current BPs use is expected.
The results of the residual confounding analysis obtained by
means of the rule-out approach are presented in Figure 5. An
unmeasured confounder is expected to be positively and negatively
associated with UGIC risk in box A and B respectively. Let us
assume a 10% prevalence of exposure to a hypothetical
unmeasured factor (U). Furthermore, let us suppose that patients
exposed to U have a 4-fold increased UGIC risk than those
unexposed. In these conditions (Box A), if BPs significantly
increased the UGIC risk, then patients exposed to U would reduce
their exposure of 5.8-fold or more during the current intake of
BPs. A reduction of exposure to U of 2-fold or more would be
required: (i) for prevalence of 25% or 50%; (ii) for stronger 8-fold
confounder-outcome association. Now, let us assume that patients
exposed to U have a 4-fold reduced UGIC risk than those
unexposed (Box B). If BPs significantly increased the UGIC risk,
then patients exposed to U would increase their exposure of 4.7-
fold during the current use of BPs.
Discussion
In this large nested case-control study we found no evidence of
an increased severe UGIC risk associated with current use of BPs
compared to past use. Our findings further suggest that there is no
important difference in gastrointestinal safety between risedronate
and alendronate, neither between daily and weekly regimens. We
also found that concurrent therapy with drugs known or suspected
to increase the UGIC risk (e.g. antidepressants, antithrombotic,
corticosteroids, antihypertensive agents and NSAIDs), as well as
previous hospitalizations, did not modify the risk associated with
current use of BPs.
Comparison with literature
Our results are consistent with those of the Fracture Interven-
tion Trial (FIT) which reported a similar proportion of patients
who experienced upper GI events in the alendronate and placebo
arms, irrespectively of planned drug dose (5 mg or 10 mg) or
Figure 1. Study flow-diagram. AIFA-BEST project, Italy, 2003–2007. BPs: Bisphosphonates.
doi:10.1371/journal.pone.0073159.g001
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patients’ demographic and clinical characteristics (older age,
previous upper GI disease, NSAIDs use) [28]. In addition, our
results complied with trials on risedronate. A pooled analysis from
9 RCTs confirmed that the rate of upper GI tract adverse events
was similar across risedronate and placebo groups, and that
concomitant use of aspirin, NSAIDs, H2-receptor antagonists
and/or proton pump inhibitors did not lead to significant
between-group differences in the incidences of these events [29].
Other RCTs showed inconsistent findings. Three trials found
significant higher risk of oesophageal ulcerations among etidronate
users [15], and of perforations, ulcerations, or bleeding episodes
among etidronate users [15–31]. Pooled analyses found no
significant effects for other bisphosphonates [32,33]. Consistently
with our findings, observational studies (OSs) did not found
evidence of increased UGIC risk among BP users [15,16,19].
However, conversely to our results, BPs – NSAIDs co-therapy has
been found to increase the UGIC risk [18,19]. It should be
noticed, that our findings were obtained by contrasting current
and past use of BPs, rather than BPs use vs. placebo (or vs. no use)
as in RCTs (or in OSs). However, assuming an acute effect of BPs
on the considered outcome, past users and no users (placebo)
would be both suitable comparators for current users.
Validity of our main findings seems to have support by the
observed association between use of other drugs and the
considered outcome. For example, consistently with literature,
we found that, with respect to controls, case patients had higher
prevalence in the use of NSAIDs, antihypertensive, antithrombotic
and corticosteroid drugs, other than in the number of previous
hospitalizations [34–49].
Similarly to others [50], we found that cases had higher use of
gastroprotective drugs than controls. As we cannot suppose that
gastroprotective agents cause GI complications, rather than
protect from their onset, the more likely explanation is that
physicians more likely prescribe gastroprotective agents to patients
with a history of GI complications, or to those at whom GI
symptoms sudden occurred, i.e. to patients at higher UGIC risk.
Strengths and limitations
Several peculiar features of our study deserve to be mentioned.
First, the study is based on data from a very large unselected
population, which was made possible by the fact that in Italy a
cost-free uniformly organized healthcare system involves practi-
cally all citizens. By drawing out healthcare utilization data from
nearly 30% of the whole Italian population, we were able to build
probably one of the largest observational studies performed on the
GI safety of bisphosphonates. Our data, furthermore, reflecting
routine clinical practice, are unaffected by selective participation
and recall bias. Second, the drug prescription databases provided
highly accurate data, because reports of prescriptions by the
pharmacies are essential for reimbursement and filing an incorrect
report about dispensed drugs has legal consequences [51]. Third, a
number of sensitivity analyses confirmed the robustness of our
findings. For example, we found that neither criteria employed for
UGIC diagnosis or the length of the time-window for current BPs
use, affected our estimates. This further strengthens the evidence
that the current use of a BP is unlikely to be causally associated
with onset of serious GI complication. In addition, there was no
evidence that the observed BPs - UGIC association changed by
introducing lag-time periods of different lengths, thus excluding
the possibility that findings were affected by ‘‘measurable’’
protopathic bias [26].
Our study has a number of potential limitations regarding
selection bias, misclassification and confounding. Two sources of
selection bias need to be considered. As outcomes were drawn
from hospitalized patients, our data concerned only severe GI
complications that required hospitalization. According to a large
body of literature, an increased risk of mild gastrointestinal events
associated with BPs use was expected [52–58], but we cannot
detect them. It should be furthermore considered the possibility
that the lack of association with stomach or duodenal complica-
tions might dilute the oesophageal risk associated with BPs.
Although patients who used BPs six months before the index
date were excluded from our cohort, it is likely that prevalent users
(i.e. patients who previously took these drugs) have been included.
Prevalent users are patients who kept therapy over time and then
are expected to be less vulnerable of experiencing the outcome of
interest. Moreover, patients previously treated who already
developed GI complications, when newly treated with BPs more
likely took into account the recommendations for their use. These
issues suggest that the inclusion of prevalent users would mask a
possible positive BPs-UGIC association. We attempted to face
such a problem by calculating the magnitude of the bias
introduced by the inclusion of prevalent BPs users. This analysis
showed that, even in the case of a strong bias (say, prevalent users
currently exposed to BPs have a two-fold decreased UGIC risk
than those unexposed), the true BPs – UGIC association was about
that expected under the null. A higher proportion of prevalent
users than that observed in the subcohort for whom such data was
available, however, would have affected more strongly our
estimates.
As far as misclassification is concerned, outcome as well as
exposure, measurement errors would be considered. Because of
privacy regulations, hospital records were not available for analysis
so diagnoses cannot be scrutinized and validated. However, a high
level of accuracy for most of the ICD-9 codes used to define our
outcome was reported by Cattaruzzi et al. for the hospital discharge
Table 1. Selected tracts of the 862 cases of upper




Bisphosphonates{ 419 (48.6%) 8,055 (52.0%) 0.0559
Antidepressants` 133 (15.4%) 1,680 (10.8%) ,0.0001
Antithrombotic` 245 (28.4%) 3,317 (21.4%) ,0.0001
Gastroprotective agents` 241 (28.0%) 2,867 (18.5%) ,0.0001
Corticosteroids` 119 (13.8%) 1,046 (6.8%) ,0.0001
Statins` 70 (8.1%) 1,549 (10.0%) 0.0735
Calcium channel blockers` 136 (15.8%) 2,115 (13.6%) 0.0763
Other antihypertensive drugs` 480 (55.7%) 6,990 (45.1%) ,0.0001
Nonsteroidal
antiinflammatory drugs`
250 (29.0%) 2,987 (19.3%) ,0.0001
Number of hospitalizations`
0 735 (85.3%) 14,781 (95.3%) ,0.0001
1 103 (11.9%) 640 (4.1%)
$2 24 (2.8%) 84 (0.6%)
{Measured over the 30-day period prior the index date.
`Measured over the 60-day period prior the index date. Hospital admissions
considered in this count does not include hospitalization for UGIC.
*According to chi-square test or chi-square test for trend (number of previous
hospitalizations).
AIFA-BEST project, Italy, 2003–2007.
doi:10.1371/journal.pone.0073159.t001
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database similar to that used in the current study [59].
Misclassification of BPs exposure might occur because, once the
drug is dispensed, it is possible that patients did not consume it. If
this preferably happens when GI symptoms occur, again a
protopathic bias is introduced, in this case without any possibility
to control for it.
Finally, as for all observational studies, there is always some
concern for residual confounding due to unmeasured factors. For
example, under the assumption that use of BPs increases the
UGIC risk, over-the-counter gastroprotective agents might be
assumed by some patients once GI symptoms occur, so selectively
reducing their outcome risk. On the other hand, the assumption of
over-the-counter NSAIDs might be reduced when GI symptoms
occur, again reducing the outcome risk. We attempted to face such
a problem by calculating the magnitude of association with current
use of BPs and risk of UGIC that a hypothetical unmeasured
confounder would need to make statistically significant the BPs –
UGIC association. This analysis showed that, even in the case of a
highly prevalent confounder (say, over-the-counter agents would
be used by the 50% of the study population) and of a strong
confounder-outcome association (say, over-the-counter gastropro-
tective or NSAIDs would be able to cut by half and to double the
UGIC risk respectively), the exposure to this factor would be
strongly imbalanced between current and past use of BPs (say,
more than 3.6-fold increased or reduced over-the-counter use
would happen during the current use of BPs) to make significant
the relationship between current use of BPs and UGIC risk. It
should be noticed, however, that the confounding model employed
assumes a confounder entirely independent of the factors adjusted
for in the naı̈ve analysis. If, as in our case, unmeasured confounder
is strongly correlated to the confounders already adjusted for, the
Figure 2. Adjusted odds ratios (and 95% confidence intervals) of upper gastrointestinal complications associated with current use
of bisphosphonates within various patient subgroups. AIFA-BEST project, Italy, 2003–2007. Odds ratios estimated with conditional
logistic regression model. Estimates concerning main analysis were unadjusted and adjusted for use of other drugs and for the number
hospitalizations in the 60-day period prior the index date. Estimates concerning subgroup analysis were obtained by including the interaction terms
combining the effect of current use of BPs together with BPs type and regimen dispensed during the current period, concurrent use of other drugs
and number hospitalizations in the 60-day period prior the index date. P-values concern comparison of BPs effect across patient subgroups or along
increasing number of hospitalizations. BPs: Bisphosphonates.
doi:10.1371/journal.pone.0073159.g002
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Figure 3. Influences of diagnostic criteria for upper gastrointestinal complications (panel A), length of time-window for current use
of bisphosphonates (panel B), and of controlling for protopathic bias (panel C) on the observed odds ratio for upper
gastrointestinal complications associated with current use of bisphosphonates. AIFA-BEST project, Italy, 2003–2007. Estimates are
adjusted for use of other drugs and number of hospitalizations in the 60-day period prior the index date. Details for diagnostic criteria are reported in
Appendix S1. For an explanation of methods for controlling protopathic bias see the ‘‘Sensitivity analysis’’, subsection of the ‘‘Methods’’ section. BPs:
Bisphosphonates.
doi:10.1371/journal.pone.0073159.g003
Figure 4. Modelled influence of the inclusion of prevalent BPs users on the true association between current BPs and UGIC risk.
AIFA-BEST project, Italy, 2003–2007. The graph indicates the trend of the true effect of BPs current use on the UGIC risk (e.g. the odds ratio
which we would have observed if only incident users were included) according to different values of the BPs – UGIC association among prevalent
users. For an explanation see the ‘‘Sensitivity analysis’’, subsection of the ‘‘Methods’’ section. BPs: Bisphosphonates. UGIC: Upper gastrointestinal
complication.
doi:10.1371/journal.pone.0073159.g004
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impact of unmeasured confounder could be much smaller than the
model indicates [60].
Conclusion
In summary, this large nested case-control study provides
further evidence that current use of BPs (as alendronate and
risedronate dispensed once-daily or once-weekly) for primary
prevention of osteoporotic fractures is not associated with an
increased risk of severe gastrointestinal complications.
Supporting Information
Appendix S1 Drugs and diagnoses codes used for the
study purpose. ATC and ICD9 codes used to identify the
exposure of interest, the covariates and the considered diseases.
(DOC)
Appendix S2 Independent Ethics Committees (IEC) list.
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Figure 5. Modelled influence of a hypothetical confounder unaccounted for in the adjustments already performed in the main
analysis according with the direction of its effect on the outcome (i.e. positive and negative associations as reported in boxes A
and B, respectively), and with its prevalence in the study population (p). AIFA-BEST project, Italy, 2003–2007. The graphs indicate
what combinations of confounder – UGIC and confounder – current BPs exposure would be required to make statistically significant the observed
association between current use of BPs and hospitalization for UGIC. For an explanation see the ‘‘Sensitivity analysis’’, subsection of the ‘‘Methods’’
section. BPs: Bisphosphonates. UGIC: Upper gastrointestinal complication.
doi:10.1371/journal.pone.0073159.g005
Bisphosphonates and Gastrointestinal Complications
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e73159
Author Contributions
Analyzed the data: AG. Wrote the paper: AG GC. Study planning: GM
GC AZ. Statistical support: GC AZ LS. Informatic support: GDV. Data
extraction: LCD DG RG AV TS FC. Results interpretation under the
pharmacological and clinical prospective: GM FL RG APC AV LCD.
Results interpretation: AG LS AZ GDV LCD FL FC APC AV DG RG
AV TS GM GC.
References
1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and
Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA
285:785–95.
2. Kai MC, Anderson M, Lau EM (2003) Exercise interventions: defusing the
world’s osteoporosis time bomb. Bull World Health Organ 81:827–30.
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